Steroid Bridge Therapy: Why Prednisone May Be Used While Waiting for Another Treatment

Many people with inflammatory bowel disease leave an appointment holding two prescriptions at once. One is prednisone, meant to calm a flare quickly. The other is a longer-term treatment, often a biologic or another advanced therapy, that will take weeks to reach full effect. The same clinician who prescribed the steroid then explains that the goal is to stop it as soon as possible. That combination confuses a lot of patients. The concept behind it has a name: steroid bridge therapy. Understanding what the bridge is meant to do, how long it usually lasts, and what to watch for while you are on it makes the whole sequence easier to follow.

What steroid bridge therapy means in IBD

Bridge therapy describes using a fast-acting drug to control disease activity during the window before a slower, longer-term treatment starts working. Corticosteroids fill that role in IBD because they suppress inflammation quickly and reliably during a flare. A 2025 review of corticosteroid use in inflammatory bowel disease published in Clinical Gastroenterology and Hepatology describes their appropriate role in induction of remission alongside a real risk of overuse when the duration is not planned in advance.

The bridge exists because the drugs that keep IBD in remission do not work fast. In the GEMINI 1 trial of vedolizumab in ulcerative colitis, the primary induction endpoint was measured at week 6, and thiopurines take longer still. The American Gastroenterological Association's living guideline on moderate-to-severe ulcerative colitis suggests against thiopurine monotherapy for induction of remission while supporting it for maintenance after corticosteroids have induced remission. That split is the clearest illustration of the bridge idea in a guideline document.

Why prednisone is not the long-term plan

Steroids control symptoms without keeping disease in remission over time. The 2025 ACG clinical guideline update for ulcerative colitis in adults issues a strong recommendation against systemic corticosteroids, budesonide MMX, or topical corticosteroids for maintenance of remission, and frames corticosteroid-free remission as the treatment target. The National Institute of Diabetes and Digestive and Kidney Diseases makes the same point in plainer terms, noting that doctors typically do not prescribe corticosteroids for long-term use or to maintain remission.

Long-term outcome data explain why guideline writers are firm about this. In a population-based study of the natural history of corticosteroid therapy in IBD, most patients responded within 30 days, but one year after that first steroid course only 32% of Crohn's disease patients and 49% of ulcerative colitis patients had a prolonged response. Twenty-eight percent of the Crohn's group and 22% of the ulcerative colitis group had become corticosteroid dependent, and 38% and 29% respectively had undergone surgery. Steroids buy time. The treatment that follows them determines what the next year looks like.

How long the bridge usually lasts

There is no single schedule that applies to everyone, and the taper your clinician writes will reflect your disease severity, how quickly you respond, and which therapy is being started. What is typical is a limited course rather than an open-ended one. The British Society of Gastroenterology's guidance on corticosteroids in IBD describes prednisolone 40 mg daily as a standard induction dose with gradual reduction as symptoms improve, and emphasizes planning the transition to disease-modifying therapy before the steroid course finishes.

An international consensus on corticosteroid management in IBD clinical trials published in Gastroenterology in 2025 recommends minimizing corticosteroid exposure through expedited tapering and shorter fixed-dosing periods that more closely reflect clinical practice, and proposes standardized definitions for corticosteroid-free remission. If you are unsure how long your own bridge is meant to be, that is a reasonable and specific question to bring to your prescribing clinician: what dose, over how many weeks, and what happens if symptoms return partway down.

Prednisone side effects to watch for

The FDA-approved prescribing information for prednisone lists a wide range of adverse reactions, including sodium and fluid retention, elevated blood pressure, decreased carbohydrate tolerance and unmasking of latent diabetes, and psychiatric effects ranging from euphoria, insomnia, and mood swings to severe depression. Musculoskeletal effects include osteoporosis and vertebral compression fractures, and ophthalmic effects include posterior subcapsular cataracts, raised intraocular pressure, and glaucoma. The label also notes decreased resistance to infection and the possibility that new infections appear during treatment.

Infection risk is documented in IBD populations specifically. In more than five years of follow-up in the TREAT registry of 6,273 Crohn's disease patients, prednisone use was independently associated with serious infection at a hazard ratio of 1.57 and with mortality at a hazard ratio of 2.14. Tracking symptoms as they appear, with dates and doses, gives your care team something concrete to work with when deciding how fast the bridge can be crossed.

What to do when the bridge does not hold

Some people cannot come off steroids on the planned schedule. Two terms describe this. The British Society of Gastroenterology defines steroid dependence as being unable to reduce below the equivalent of prednisolone 10 mg per day, or budesonide 3 mg per day, within three months of starting steroids without disease becoming active again. Steroid refractory disease is defined as active disease despite prednisolone 1 mg per kilogram per day for four weeks. Either situation is a signal to reassess the long-term therapy rather than to extend the steroid course.

Tapering is also a physiological process, not only a disease one. The prednisone label states that drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage, and advises against abrupt discontinuation after prolonged therapy. That is why the taper is written out rather than left to judgment, and why stopping on your own carries risk. If symptoms return as the dose comes down, report it rather than adjusting the dose yourself.

The bridge period is short by design and consequential out of proportion to its length. It is the window in which your care team learns how you responded to steroids, whether the new therapy is taking hold, and which side effects matter for you. Keeping a dated record of doses, symptoms, and questions turns that window into usable information for the conversation that decides what comes after prednisone.